Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line MK-1084 + cetuximab + mFOLFOX6 versus mFOLFOX6 with or without bevacizumab in KRAS G12C-mutant colorectal cancer
MOH_2025-06-19_014090Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of calderasib, cetuximab, oxaliplatin, folinic acid, fluorouracil and 1 more in colorectal cancer (CRC) (3 arms), sponsored by Merck & Co. Started May 2025; status: recruiting.
02
Drugs
calderasibcetuximaboxaliplatinfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on MOH_2025-06-19_014090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-19_014090.